# Pediatric Schizophrenia Efficacy and Safety Study

> **NCT01911429** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 327 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lurasidone 40 mg
- **DRUG:** Lurasidone 80 mg
- **DRUG:** Placebo 40 or 80 mg

## Key facts

- **NCT ID:** NCT01911429
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2017-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01911429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01911429, "Pediatric Schizophrenia Efficacy and Safety Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01911429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*